2019
DOI: 10.1016/j.amjmed.2018.12.023
|View full text |Cite
|
Sign up to set email alerts
|

Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

19
122
0
9

Year Published

2019
2019
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 118 publications
(150 citation statements)
references
References 24 publications
19
122
0
9
Order By: Relevance
“…There have been a number of observational studies examining the safety and effectiveness of NOACs with conflicting results [15][16][17][18][19][20][21][22][23][24][25][26]34]. When comparing results with other observational studies, it is important to note that rivaroxaban was the most frequently prescribed NOAC in our cohort (71.5%).…”
Section: Discussionmentioning
confidence: 90%
See 2 more Smart Citations
“…There have been a number of observational studies examining the safety and effectiveness of NOACs with conflicting results [15][16][17][18][19][20][21][22][23][24][25][26]34]. When comparing results with other observational studies, it is important to note that rivaroxaban was the most frequently prescribed NOAC in our cohort (71.5%).…”
Section: Discussionmentioning
confidence: 90%
“…However, the reduction in mortality risk as a secondary endpoint in clinical trials was not significant for NOACs [7][8][9], with the exception of edoxaban [14]. While some observational studies suggest a reduced risk of all-cause mortality among NOAC users, as compared to VKAs [15][16][17][18][19][20][21][22], the evidence is conflicting. Importantly, many observational studies use an ever versus never exposure definition that does not permit switching between medications.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…In 3285 elderly patients from the PREFER in AF registries, the primary net composite end-point (ischemic cardiovascular events and major bleeding) was lower with DOACs than with VKAs (6.6% vs 9.1%, respectively, OR 0.71, 95% CI 0.51-0.99), with a net clinical benefit of DOACs primarily due to lower rates of major bleedings [24]. In a propensity score adjusted analysis of a retrospective US Medicare cohort of new-user AF patients who initiated warfarin or full doses of dabigatran, rivaroxaban and apixaban, compared to warfarin each DOAC was associated with reduced risks of thromboembolic stroke (20-29%), intracranial hemorrhage (35-62%) and mortality (19-34%) [25].…”
Section: Real World Patients Frailty and Geriatric Syndromesmentioning
confidence: 99%
“…В 2019 г. опубликованы результаты крупного ретроспективного когортного исследования [14], выполненного по заданию и при финансировании американской организации FDA (Food and Drug Administration). В нем принимали участие 448 944 пациента с неклапанной ФП в возрасте ≥ 65 лет, зарегистрированные в системе US Medicare, которые получали варфарин (n = 183 318) или один из ППОАК: дабигатран (150 мг 2 раза в день; n = 86 198), ривароксабан (20 мг 1 раз в день; n = 106 389) или апиксабан (5 мг 2 раза в день; n = 73 039) в период с октября 2010 г. по сентябрь 2015 г. По сравнению с варфарином все ППОАК снижали риск инсульта на 20-29% (р = 0,002 для дабигатрана; р < 0,001 для ривароксабана и апиксабана), внутричерепного кровоизлияния -на 35-62% (р < 0,001 для всех ППОАК) и общую смертность -на 19-34% (р < 0,001 для всех ППОАК).…”
unclassified